Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug BHV-1300 tested for Graves' disease safety

NCT ID NCT06980649

Disease control Sponsor: Biohaven Therapeutics Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This early study is testing a new drug called BHV-1300 in 15 people with Graves' disease. The main goal is to see if the drug is safe and to check how it affects certain markers of the disease. This is a phase 1 trial, so it's one of the first steps in testing this treatment in humans.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: 1\. Participants must have serologically confirmed Graves' Disease. Key Exclusion Criteria: 1. History of hyperthyroidism not caused by Graves' Disease (e.g., toxic adenoma or toxic multinodular goiter) and/or history of thyroid storm within six weeks of the Baseline visit. 2. History of treatment with radioactive iodine or thyroid surgery.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Graves disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autoimmune disease endocrine system disorder Graves disease hyperthyroidism thyroid gland disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Graves disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    18 sites in 2 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Site-001

    RECRUITING

    Kotara, 2289, Australia

  • Site-002

    RECRUITING

    Torquay, 3228, Australia

  • Site-003

    RECRUITING

    Melbourne, 3128, Australia

  • Site-004

    RECRUITING

    Fitzroy, 3065, Australia

  • Site-006

    RECRUITING

    St Leonards, 2065, Australia

  • Site-008

    RECRUITING

    Parkville, 3050, Australia

  • Site-010

    RECRUITING

    Oaklands Park, 5046, Australia

  • Site-011

    RECRUITING

    Herston, 4029, Australia

  • Site-100

    RECRUITING

    Miami, Florida, 33126, United States

  • Site-101

    RECRUITING

    Houston, Texas, 77095, United States

  • Site-103

    RECRUITING

    South Gate, California, 90280, United States

  • Site-104

    RECRUITING

    Columbus, Georgia, 31904, United States

  • Site-105

    RECRUITING

    Shavano Park, Texas, 78231, United States

  • Site-106

    RECRUITING

    Houston, Texas, 77054, United States

  • Site-107

    RECRUITING

    Memphis, Tennessee, 38119, United States

  • Site-108

    RECRUITING

    Greenville, North Carolina, 27834, United States

  • Site-109

    RECRUITING

    Dallas, Texas, 75246, United States

  • Site-110

    RECRUITING

    Canton, Ohio, 44718, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.